India Globalization Capital (NYSE American: IGC) is strategizing the marketing of its products and select target markets for continued growth. A recent article highlights next year’s and future year’s prospects and IGC plans, stating, “[IGC] sees opportunities in 2018, primarily from the distribution, in Germany, of its cannabinoid-based therapies, including IGC-AD1 (Hyalolex). It also sees the commercialization in 2018 of Hyalolex in a non-inebriating liquid supplement version. IGC has identified a number of U.S. states, as well as Canada and Germany, as target markets in the future.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
India Globalization Capital, Inc.’s (NYSE: IGC) Future Business Strategy
